COMP <GO>
CSTL vs FRNM // NET PROFIT MARGIN
Castle Biosciences Inc. (NASDAQ) VS. Freenome Inc. (NASDAQ) • 15-METRIC TALLY: CSTL 3
— FRNM 2
■ METRIC PARITY
LAST: $38.51 (+4.99%) • MKT CAP: $1.18B
net-margins
-7.00%
LAST: $12.86 (-4.32%) • MKT CAP: $1.38B
net-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CSTL VS. FRNM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CSTL | FRNM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -9.30% | -3.40% | -5.90 | FRNM | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.41% | -0.06% | +2.47 | CSTL | /fcf-yield <GO> |
| Operating Margin | -12.40% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -7.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 3.70% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.97 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 1/9 | +5.00 | CSTL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.6 | 43.3 | +21.30 | CSTL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.18B | $1.38B | -$205.3M | FRNM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CSTL REV | FRNM REV | CSTL GROSS % | FRNM GROSS % | CSTL FCF | FRNM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $344.2M | $0 | 79.4% | — | $28.3M | -$864.7K |
| FY 2024 | $332.1M | $0 | 81.9% | — | $36.5M | — |
| FY 2023 | $219.8M | — | — | — | -$5.6M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CSTL // BETA —
FRNM // BETA —